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Impact of COPD on COVID‑19 
prognosis: A nationwide 
population‑based study in South 
Korea
Sang Chul Lee1,2,6, Kang Ju Son3,4,6, Chang Hoon Han1, Seon Cheol Park1,7* & Ji Ye Jung5,7*
Underlying chronic respiratory disease may be associated with the severity of coronavirus disease 
2019 (COVID‑19). This study investigated the impact of chronic obstructive pulmonary disease (COPD) 
on the risk for respiratory failure and mortality in COVID‑19 patients. A nationwide retrospective 
cohort study was conducted in 4610 patients (≥ 40 years old) infected with COVID‑19 between January 
20 and May 27, 2020, using data from the Ministry of Health and Welfare and Health Insurance Review 
and Assessment Service in Korea. The clinical course and various clinical features were compared 
between COPD and non‑COPD patients, and the risks of respiratory failure and all‑cause mortality 
in COPD patients were analyzed using a multivariate logistic regression model. Among 4610 COVID‑
19 patients, 4469 (96.9%) and 141 (3.1%) were categorized into the non‑COPD and COPD groups, 
respectively. The COPD group had greater proportions of older (≥ 60 years old) (78.0% vs. 45.2%, 
P < 0.001) and male (52.5% vs. 36.6%, P < 0.001) patients than the non‑COPD group. Relatively greater 
proportions of patients with COPD received intensive critical care (7.1% vs. 3.7%, P = 0.041) and 
mechanical ventilation (5.7% vs. 2.4%, P = 0.015). Multivariate analyses showed that COPD was not a 
risk factor for respiratory failure but was a significant independent risk factor for all‑cause mortality 
(OR = 1.80, 95% CI 1.11–2.93) after adjustment for age, sex, and Charlson Comorbidity Index score. 
Among COVID‑19 patients, relatively greater proportions of patients with COPD received mechanical 
ventilation and intensive critical care. COPD is an independent risk factor for all‑cause mortality in 
COVID‑19 patients in Korea.
Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), has caused a pandemic, with considerable morbidity and  mortality1. The severity of disease 
ranges from asymptomatic infections to mild self-limiting upper respiratory tract illness, severe pneumonia with 
respiratory failure, or  death2. Evidence and experience regarding treatment for COVID-19 are lacking, although 
comorbidities are important factors influencing patient prognosis.
Patients with chronic respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), have 
a high risk for COVID-19 infection due to their poor underlying lung reserve and increased expression of 
angiotensin-converting enzyme 2 (ACE-2) receptor in the small  airways3. However, comprehensive analyses 
of the risks, disease severity, and clinical course in COVID-19 patients with COPD are  lacking1,4–6. Guan et al. 
evaluated the risk for serious adverse outcomes in COVID-19 patients in China by stratifying them according to 
the number of  comorbidities4. A greater number of comorbidities was correlated with worse clinical outcomes, 
and COPD patients had the highest hazard ratio (2.68) for admission to the ICU, invasive ventilation, or death 
among the patients with various types of chronic underlying  diseases4.
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However, previous studies have had important limitations, with relatively small sample sizes and data obtained 
from a single center or region. Moreover, the impact of COPD on morbidity and mortality was not assessed in 
the context of other demographic factors, such as age, sex, or other comorbidities. In addition, the diagnosis and 
definition of COPD has not been clearly stated in previous  reports1,4–6.
Therefore, we conducted a nationwide population-based study to analyze the impact of COPD on the risks 
of disease progression and mortality among COVID-19 patients in South Korea.
Methods
Study design. We conducted a retrospective cohort study to evaluate the risk for respiratory failure and 
mortality in COVID-19 patients with COPD using data from the Ministry of Health and Welfare and the Health 
Insurance Review and Assessment Service (HIRA) in South Korea. National Health Insurance (NHI) in Korea 
is a compulsory social insurance system and insures about 97% of the population. The remaining population is 
covered by Medical Aid. All hospitals and clinics in Korea submit medical records of patients covered by NHI 
and Medical Aid to the Health Insurance Review and Assessment (HIRA) office for review to be reimbursed for 
any healthcare services  provided7. The HIRA claim database includes 46 million patients per year, approximately 
90% of the total population in Korea, from almost 80,000 healthcare service  provides8. The HIRA dataset com-
prises all insurance benefit claims by medical service providers and includes general sociodemographic infor-
mation, diagnoses according to the 10th revision of the International Statistical Classification of Diseases and 
Related Health Problems (ICD-10), the medical institution, medications prescribed, medical costs and survival 
 status9. The HIRA shared nationwide data on 7590 patients infected with COVID-19 between January 20 (date 
of the first confirmed case) and May 27, 2020, with researchers in South Korea.
The present study covered three different time periods: the classification period, measurement period, and 
COVID-19 period (Fig. 1). Among 7590 COVID-19 patients, 4610 COVID-19 patients aged 40 years or older 
were categorized into the COPD and non-COPD groups according to their history of COPD diagnosis and 
treatment, and their comorbidities were assessed during the classification period (January 1, 2017–December 
31, 2018). During the measurement period (January 1–December 31, 2019), COPD severity, the number of acute 
exacerbations, and drug adherence were evaluated. During the COVID-19 period, information on sex, age, region 
of residence, and medical aid was collected at the time of COVID-19 diagnosis. Subsequently, various clinical 
parameters and outcomes, such as length of hospital stay, overall medical expenses, number of intensive care 
unit (ICU) admissions, length of ICU stay(s), respiratory failure, and mortality, were evaluated and compared 
between those with and without COPD.
Study subjects. HIRA released, via an online portal (accessible at https ://hira-covid 19.net), de-identified 
records for 7590 patients who were confirmed to be infected with COVID-19 by a reverse transcription poly-
merase chain reaction test for SARS-CoV-2 using nasopharyngeal swab or sputum  specimens10. Further data 
linked to all of the claim records of these COVID-19 patients since January 2017 were provided from the HIRA 
database.
COPD was defined by the prescription of COPD medication(s) at least two times per year with a diagnosis of 
COPD (ICD-10 code: J43 and J44 except J43.0) during the enrollment period. The COPD medications included 
1 Jan  2017 –31 Dec 2018 1 Jan –31 Dec 2019
Classification period Measurement period COVID-19 period
Period Extracted Data
● Classification period 
① Identification of COPD patients with ICD-10 codes (J43 and 
J44 except J43.0)
② Comorbidities
● Measurement period 
① Establishment of COPD severity according to COPD 
medication use and history exacerbations 
② History of acute exacerbation
③ Drug adherence assessment (medication possession rate)
● COVID-19 period ① Clinical outcomes during hospitalization or ICU care
20 Jan –27 May 2020
Figure 1.  Study scheme. Information on the study population was collected for three different periods: 
enrollment, measurement, and COVID-19. COPD patients were identified, and the baseline characteristics of 
patients were assessed during the enrollment period. COPD severity, the number of acute exacerbations, and the 
medication possession ratio were evaluated during the measurement period. COVID-related clinical outcomes 
were evaluated during the COVID-19 period. COVID-19, coronavirus disease 2019; COPD, chronic obstructive 
pulmonary disease; ICD-10, 10th revision of the International Statistical Classification of Diseases and Related 
Health Problems; ICU, intensive care unit.
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long-acting muscarinic antagonists (LAMAs), long-acting beta-2 agonists (LABAs), a combination of LAMA 
and LABA (LAMA/LABA), a combination of inhaled corticosteroid (ICS) and LABA (ICS/LABA), short-acting 
muscarinic antagonists (SAMAs), short-acting beta-2 agonists (SABAs), phosphodiesterase-4 (PDE-4) inhibi-
tors, systemic beta agonists, and methylxanthine. Once identified, 141 COPD patients were compared to 4469 
non-COPD patients, all of whom had confirmed cases of COVID-19.
Definitions. The Charlson Comorbidity Index (CCI), which is used to identify the risk for mortality or 
patients’ resource use based on comorbidities, was recorded as previously  described11,12. The CCI was calculated 
by summing the points for each relevant comorbidity, obtained based on diagnostic codes in the HIRA data dur-
ing the enrollment period (Supplementary Table 1).
COPD severity was assessed according to the types of medications prescribed and the number of exacerba-
tions during the measurement period. Then, COPD patients were categorized into severe and non-severe groups. 
The group with severe disease included those who had experienced exacerbations two or more times and those 
who had been prescribed triple therapy (ICS, LABA, and LAMA), PDE-4 inhibitors, or low-dose macrolides.
An acute exacerbation was defined when the diagnostic code for COPD (J43 and J44 except J43.0) was present 
in conjunction with any of the following: treatment with an antibiotic or systemic corticosteroids, hospitalization, 
and/or an emergency room  visit13.
Drug adherence was determined using the medication possession rate (MPR) for COPD medications. The 
MPR was calculated as the sum of all days’ supplies of prescriptions filled divided by the time from the first filling 
of a prescription until the end of the measurement period. The patients were categorized into three adherence 
groups: low (MPR < 0.5), partial (MPR 0.5–0.79), and complete (MPR ≥ 0.8)  adherence14. The previously listed 
COPD medications were used to measure MPR status.
Respiratory failure was defined as the use of invasive or noninvasive mechanical ventilation or extracorporeal 
membrane oxygenation (ECMO).
Statistical analyses. We compared COVID-19 patients with and without COPD using χ2 test or Fisher 
exact test for categorical variables and Student’s t-test or Mann–Whitney U-test for continuous variables as 
indicated. To identify risk factors independently associated with the COVID-19-related clinical outcomes of 
respiratory failure and mortality, we conducted multivariate analyses using a logistic regression model. Risk 
factors are reported as adjusted odds ratios (ORs) with 95% confidence intervals (CIs). A P value < 0.05 was 
considered statistically significant. All statistical analyses were performed with SAS, version 9.4 (SAS Institute, 
Cary, NC, USA).
Ethics approval. The Institutional Review Board of Severance Hospital approved the study protocol in 
accordance with guidelines of the Declaration of Helsinki (IRB No.: 4–2020–0248) and waived the need to 
obtain informed consent from the patients due to the retrospective nature of the study and the use of a de-
identified database. All personal identification information was anonymized.
Results
Patient characteristics. Among 7590 patients infected with COVID-19 between January 20 and May 27, 
2020, 4610 were aged 40 years or older. During the classification period, 4469 (96.9%) patients and 141 (3.1%) 
patients were categorized into the non-COPD and COPD groups, respectively. Among the COPD patients, 114 
(80.9%) and 27 (19.1%) were classified into the non-severe and severe groups, respectively (Fig. 2).
The baseline demographics of the study population are shown in Table 1. The COPD group had greater pro-
portions of older (≥ 60 years old) (78.0% vs. 45.2%, P < 0.001) and male (52.5% vs. 36.6%, P < 0.001) patients than 
the non-COPD group. Most comorbidities were more frequently observed in the COPD group than in the non-
COPD group, and hypertension was the most common comorbidity in both groups. The proportion of patients 
with a CCI score of 4 or higher was 61.7% in the COPD group and 19.4% in the non-COPD group (P < 0.001). 
In the COPD group, 72.3% and 24.1% of the patients had low and complete MPRs, respectively. Moreover, 73.1% 
of the COPD patients experienced no moderate to severe exacerbations during the measurement period before 
contracting COVID-19; 12.8% experienced exacerbations two or more times.
Clinical outcomes of COVID‑19 in COPD and non‑COPD patients. Table 2 compares the clinical 
outcomes between the non-COPD and COPD groups. The rate of hospitalization, duration of hospitalization, 
and total amount of COVID-19-related medical resources did not differ between the two groups. However, 
the proportions of patients who received ICU care (7.1% vs. 3.7%, P = 0.041) and mechanical ventilation (5.7% 
vs. 2.4%, P = 0.015) were higher in the COPD group, although none of the COPD patients received ECMO. In 
addition, all-cause mortality was higher in the COPD group than in the non-COPD group (19.2% vs. 4.5%, 
P < 0.001).
Risk factors for respiratory failure and all‑cause mortality in COVID‑19 patients. Table 3 shows 
multivariate analyses of risk factors for respiratory failure and all-cause mortality in COVID-19 patients. An 
age of 60 years or older (OR = 5.05, 95% CI 2.99–8.52), male sex (OR = 2.06, 95% CI 1.42–3.01), and higher CCI 
(per one-point increase; OR = 1.14, 95% CI 1.06–1.22) were independent risk factors for respiratory failure. 
Moreover, an age of 60 years or older (OR = 12.02, 95% CI 7.03–20.54), male sex (OR = 1.74, 95% CI 1.31–2.30), 
CCI (per one-point increase; OR = 1.22, 95% CI 1.16–1.28), and COPD (OR = 1.80, 95% CI 1.11–2.93) were all 
independent risk factors for all-cause mortality.
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Comparison between non‑severe and severe COPD groups. Among the COPD patients with 
COVID-19, characteristics and clinical outcomes were compared between the non-severe and severe groups 
(Supplementary Tables 2, 3, and 4). The severe group had a higher proportion of older patients (≥ 60 years old) 
(96.3% vs. 73.7%, P = 0.011) than the non-COPD group. The proportions of males, patients with each comorbid-
ity, and patients with each CCI score were similar between the two groups. However, more patients in the severe 
group showed complete MPRs (51.9% vs. 17.5%, P < 0.001), and more patients in the non-severe group had 
experienced no exacerbations during the measurement period before contracting COVID-19 (85.1% vs. 22.2%, 
P < 0.001) (Supplementary Table 2).
During the COVID-19 period, the total amount of medical resources used was higher in the non-severe 
group (6264 USD vs. 3585 USD, P = 0.003), and none of the patients in the severe group received ICU care or 
mechanical ventilation. All-cause mortality did not differ between the groups (Supplementary Table 3). Accord-
ing to multivariate analyses of risk factors associated with respiratory failure and all-cause mortality, age (per 
one year increases; OR = 1.11, 95% CI 1.05–1.17) and male sex (OR = 4.00, 95% CI 1.39–11.55) were significant 
risk factors for all-cause mortality (Supplementary Table 4).
Discussion
This is the first nationwide population study to evaluate the impact of COPD on the clinical characteristics and 
prognosis of COVID-19 patients in South Korea. Greater proportions of COPD patients needed ICU care and 
mechanical ventilation than of patients without COPD. Among the COVID-19 patients, the risk for all-cause 
mortality was approximately two times higher in patients with COPD than in those without.
According to our study, among the COVID-19 patients who were 40 years and older, 3.1% had COPD; of 
these, 7.1% received ICU care, and 5.7% received mechanical ventilation. Among the COVID-19 patients who 
received ICU care and those who received mechanical ventilation, 5.6% (10/177) and 7.0% (8/116) had COPD, 
respectively. The rate of all-cause mortality among COPD patients was 19.2%, and the proportion of COPD 
among COVID-19 non-survivors was 11.9% (27/226). Although COPD was not an independent risk factor for 
respiratory failure, it was a significant risk factor for all-cause mortality.
Since the World Health Organization declared COVID-19 a pandemic, 79,515,525 cases have been confirmed 
around the world, with 1,757,947 deaths on January 2nd,  202115. The prevalence of COPD among COVID-
19 patients ranges from 0 to 10% worldwide, although most reports are from China, particularly Wuhan or 
 Hubei3,4,16,17. In Europe, the prevalence of COPD is between 5.6 and 11%, whereas it is 2.4–5.4% in New York City 
in the United  States18–25. However, most of these studies were conducted in a single center or region, resulting in 
a small population of COVID-19 patients and an even smaller number of COVID-19 patients with  COPD3,5,17. 
Therefore, those studies have not evaluated the impact of COPD on the clinical characteristics and prognosis 
of COVID-19 patients, with the exception of Guan et al. which employed nationwide analyses in  China4. How-
ever, because all COVID-19 patients were reviewed, including those younger than 40 years old, the prevalence 
of COPD was just 1.5%. Moreover, only 24 patients with COPD were included in the analyses of the impact of 
COPD on COVID-194.
We have included all COVID-19 patients in South Korea, regardless of whether they were hospitalized or 
isolated in nonhospital community isolation facilities, termed “living and treatment centers.” Facility admission 
was initially recommended for patients with asymptomatic or mild COVID-19 cases who were under middle 
age and had no underlying comorbidities or well-controlled chronic  diseases26. However, in South Korea, only 
6.7% of patients were isolated in living and treatment centers, and 93.3% were hospitalized. In this analysis, we 
4,610 confirmed COVID-19 patients ≥ 40 years of age
4,469 COVID-19 patients without COPD 141 COVID-19 patients with COPD 
7,590 cases of COVID-19 in the administrative claims database (Project name: 





Figure 2.  Flowchart of the study cohort. Of 7590 COVID-19 patients, 4610 were aged 40 years or older. 
During the enrollment period, 4469 and 141 patients were categorized into the non-COPD and COPD groups, 
respectively. Among the COPD patients, 114 and 27 were classified into the non-severe and severe groups, 
respectively. COPD was defined by the ICD-10 codes and COPD medications prescribed during the enrollment 
period. The severity of COPD was classified based on the types of medications prescribed and the number 
of exacerbations during the measurement period. COVID-19 coronavirus disease 2019; COPD, chronic 
obstructive pulmonary disease; ICD-10, 10th revision of the International Statistical Classification of Diseases 
and Related Health Problems.
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Table 1.  Patient characteristics. Data are presented as numbers (%). COPD chronic obstructive pulmonary 
disease, CCI Charlson comorbidity index, MPR medication possession ratio. *Data are only for COPD 
patients. MPR was calculated as the sum of all days’ supplies of prescriptions filled divided by the time from 
the first filling of a prescription until the end of the measurement period. Patients were categorized into three 
adherence groups: low (MPR < 0.5), partial (MPR 0.5–0.79), and complete (MPR ≥ 0.8) adherence. † Data are 
only for COPD patients. Exacerbation was defined when the diagnostic code for COPD (J43 and J44 except 
J43.0) was present in conjunction with any of the following: (1) treatment with an antibiotic or systemic 
corticosteroids, (2) hospitalization, or (3) an emergency room visit.
Characteristics Non-COPD (n = 4469) COPD (n = 141) P-value
Age, years
40–59 2447 (54.8) 31 (22.0) < 0.001
 ≥ 60 2022 (45.2) 110 (78.0)
Sex, male 1636 (36.6) 74 (52.5) < 0.001
Comorbidities
Hypertension 1432 (32.0) 85 (60.3) < 0.001
Diabetes 1110 (24.8) 74 (52.5) < 0.001
Ischemic heart disease 309 (6.9) 33 (23.4) < 0.001
Angina pectoris 286 (6.4) 28 (19.9) < 0.001
Myocardial infarction 62 (1.4) 8 (5.7) < 0.001
Heart failure 232 (5.2) 39 (27.7) < 0.001
Cerebrovascular disease 450 (10.1) 38 (26.9) < 0.001
Rheumatological disease 251 (5.6) 12 (8.5) 0.145
Liver disease 229 (5.1) 11 (7.8) 0.159
Malignancies 276 (6.2) 20 (14.2) < 0.001
CCI score
0–1 2354 (52.7) 13 (9.2) < 0.001
2 739 (16.5) 30 (21.3)
3 511 (11.4) 11 (7.8)
 ≥ 4 865 (19.4) 87 (61.7)
MPR group*
Low – 102 (72.3) < 0.001
Partial – 5 (3.6)
Complete – 34 (24.1)
Number of exacerbations†
0 – 103 (73.1) < 0.001
1 – 20 (14.2)
≥ 2 – 18 (12.8)
Table 2.  Clinical outcomes of COVID-19 in COPD and non-COPD patients. Data are presented as numbers 
(%) or means ± standard deviations. COVID-19 coronavirus disease 2019, COPD chronic obstructive 
pulmonary disease, USD United States dollar, ICU intensive care unit, ECMO extracorporeal membrane 
oxygenation.
Variables Non-COPD (n = 4469) COPD (n = 141) P-value
Total amount of medical resource use, USD 5205 ± 6832 5751 ± 6720 0.349
Hospital admission
Number of patients 4169 (93.3) 134 (95.0) 0.412
Length of stay, days 24.2 ± 14.9 25.9 ± 19.1 0.304
ICU care
Number of patients 167 (3.7) 10 (7.1) 0.041
Length of stay, days 10.8 ± 9.0 9.7 ± 8.8 0.699
Mechanical ventilation 108 (2.4) 8 (5.7) 0.015
ECMO 21 (0.5) 0 (0) 0.415
All-cause mortality 199 (4.5) 27 (19.2) < 0.001
6
Vol:.(1234567890)
Scientific Reports |         (2021) 11:3735  | https://doi.org/10.1038/s41598-021-83226-9
www.nature.com/scientificreports/
limited the age to 40 years or older to focus on the age group in which COPD is prevalent. In addition, previous 
studies did not clearly state how the COPD diagnosis was defined, and underestimation of COPD is suspected 
in overburdened hospitals during the COVID-19 pandemic. We analyzed the HIRA data according to diagnostic 
codes and medical prescriptions. Our COPD group consisted of patients with significant airway disease who were 
receiving COPD maintenance medications; thus, COPD patients with asymptomatic mild disease who were not 
receiving any COPD maintenance medications would have been missed.
Although it is important to keep in mind the small number of COPD patients, it was notable that the propor-
tion of patients with progression to severe COVID-19 among COPD patients has ranged from 20 to 50% in other 
 studies4–6,27. This proportion is higher than that reported in our study because our criteria for severe disease were 
confined to respiratory failure, including the need for mechanical ventilation, ECMO, or ICU care. The rate of all-
cause mortality among COPD patients in previous studies ranged from 8.6 to 25%, while the proportion of COPD 
among COVID-19 non-survivors ranged from 2.8 to 20.0%1,4,20,28. During the unexpected COVID-19 pandemic, 
clinical progression and the outcomes of management vary depending on the status of medical resources and 
accessibility of medical services in each country. Some countries can provide testing and hospitalization only for 
patients with severe disease. In South Korea, patients can easily access the hospital, and medical services were 
provided promptly and equitably to most patients with suspected or confirmed cases of COVID-19.
Increasing age, cardiovascular comorbidities, and high Sequential Organ Failure Assessment scores were 
significant risk factors for mortality from COVID-1929. We also found older age (≥ 60 years old), male sex, and 
higher CCI to be significant risk factors for respiratory failure and all-cause mortality, as was COPD comorbidity. 
COPD is a disease that occurs in later life and is associated with multiple comorbidities, including cardiovascular 
 diseases30,31. Moreover, COPD itself might have increased the risk for worse clinical outcomes due to poor lung 
function and immune modulation of the airways. However, COPD is a heterogeneous disease with variation 
in disease severity, frequency of exacerbations, and comorbidities. Further studies are warranted to determine 
which features increase the likelihood for poor outcomes in COPD with COVID-19 infection.
This study is the first to describe the impact of the severity of COPD on the clinical course of COVID-19. Our 
results demonstrate that the severity of COPD does not influence the clinical outcomes of COVID-19, including 
the length of hospital stay, need for intensive care, respiratory failure, and all-cause mortality. The total amount 
of medical resources used was higher in the non-severe than in the severe group because a larger absolute 
number of patients in the non-severe group received intensive care including mechanical ventilation. Among 
COPD patients, age and male sex were independent risk factors for all-cause mortality. However, because of the 
small number of patients with severe COPD, the impact of severity could not be thoroughly evaluated, so these 
results cannot be generalized. Moreover, our strict selection of COPD patients might have failed to identify mild 
cases with no record of COPD maintenance medication, which could affect the results of comparison between 
the severe and non-severe COPD groups. However, in a study of the impact of asthma on COVID-19, asthma 
patients with any previous acute exacerbation before COVID-19 showed mortality twice as high as those without, 
particularly in case of older age and male  sex32.
Patients with COPD were more likely to progress to severe disease, leading to a higher mortality rate than in 
those without COPD. The relationship between COPD and COVID-19 has not been fully elucidated, but several 
studies have suggested pathways related to ACE-2, to which the spike protein (S protein) of SARS-CoV-2 binds 
to gain entry into the  cell33,34. Transmembrane serine protease 2 primes the S protein to facilitate the fusion 
of the virus with cellular ACE-2  receptors35. The expression level of ACE-2 was significantly higher in COPD 
patients than in controls and in current smokers than in former or never  smokers36–38. However, the increased 
expression of ACE-2 in COPD patients would not be sufficient in and of itself to explain the observed increase 
in susceptibility and increased severity of disease.
The impact of maintenance medication for COPD including ICS, SABA, LABA, and LAMA on the clini-
cal outcomes of COVID-19 infection remain unknown. Among those, ICS has shown controversial results, 
either mitigating or exacerbating COVID-19  infections3. Recently, Schultze et al. reported that regular ICS use 
in patients with asthma or COPD did not show any beneficial role in protecting against COVID-19-related 
death, although ICS combinations showed a higher hazard ratio for COVID-19-related death compared to 
LABA–LAMA combinations, likely due to confounding related to underlying health differences between people 
who were prescribed ICS and those who were  not39. Moreover, Choi et al. reported that prior ICS use was not 
significantly associated with COVID-19 in patients with COPD or asthma, nor with clinical outcomes among 
patients with COVID-1940.
Table 3.  Multivariate analyses of risk factors associated with respiratory failure and all-cause mortality. CCI 
Charlson comorbidity index, COPD chronic obstructive pulmonary disease, OR odds ratio, CI confidence 
interval.
Variable
Respiratory failure All-cause mortality
Adjusted OR 95% CI Adjusted OR 95% CI
Age ≥ 60 years old 5.05 2.99–8.52 12.02 7.03–20.54
Sex, male 2.06 1.42–3.01 1.74 1.31–2.30
CCI, per one point increases 1.14 1.06–1.22 1.22 1.16–1.28
COPD 1.03 0.48–2.25 1.80 1.11–2.93
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Our study has several potential limitations. First, because the data were obtained from administrative claims, 
the diagnostic codes and prescribed medications may not have identified all COPD patients, such as those with 
mild COPD who were not taking COPD maintenance medications. This strict selection of COPD patients might 
have affected the results of comparison between non-severe and severe groups among COPD patients (Supple-
mentary Tables). Second, due to limitations in obtaining various types of information from the HIRA database, 
any details of medical procedures were not available and only few variables were adjusted in regression analyses. 
For example, information on smoking status was not available in the HIRA data, and smoking may be associ-
ated with the expression of ACE-2 in COPD patients. Third, further detailed information about inhalers used as 
maintenance medication to control COPD and the amount of systemic corticosteroids were not analyzed with 
regard to their effects on the risk for and progression of COVID-19. Moreover, although we analyzed the number 
of previous exacerbations in COPD patients before they contracted COVID-19, the impacts of exacerbations 
were not fully evaluated because of the small number of COPD patients.
In conclusion, COPD is an independent risk factor for all-cause mortality in COVID-19 patients in Korea. 
In addition, older age, male sex, and a higher CCI score were significant risk factors for respiratory failure and 
all-cause mortality. Although the severity of COPD was not associated with clinical outcomes in COVID-19 
patients, further research is needed to investigate the association in a larger group of patients. Our study sug-
gests that close attention and special consideration with regard to COPD patients are essential to prevent the 
progression of COVID-19, leading to mortality.
Data availability
The datasets used and/or analyzed in the current study are not publicly available due to patient data privacy 
regulations pertaining to HIRA.
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